Tanzania is embarking on an ambitious journey to revolutionize its pharmaceutical sector, with plans to establish 10 new factories and revitalize existing infrastructure, significantly boosting the local production of essential medicines, including life-saving antiretroviral drugs (ARVs). This strategic shift comes as the nation grapples with evolving global health funding landscapes, particularly cuts in foreign aid.

The groundbreaking initiative was unveiled by the Minister for Health, Jenista Mhagama, during a recent parliamentary session in Dodoma. Her announcement signals a decisive move to reduce Tanzania’s reliance on imported medicines and secure a more stable and affordable healthcare future for its citizens.

Also Read : Tanzania’s Prof. Mohamed Janabi Appointed as WHO Regional Director for Africa

Minister Mhagama underscored the dual purpose of this undertaking, stating, “The primary goal of this project is to attract more investment into the pharmaceutical industry while simultaneously strengthening the national economy.”

The new facilities are slated to produce a diverse range of critical medical supplies, including ARVs, intravenous fluids (commonly known as drips), laboratory reagents, as well as various tablets and liquid medicines. This broad spectrum of production aims to meet the escalating demand for medical supplies not only within Tanzania but also across the wider East African region.

Adding to the impetus for local production, Minister Mhagama revealed a crucial factor: the recent executive orders by President Donald Trump to halt funding for the US President’s Emergency Plan for Aids Relief (PEPFAR), a significant source of foreign ARV aid for Tanzania in the past. This shift has prompted Tanzania to proactively explore new avenues to lessen its over-reliance on external assistance.

In response to these foreign aid adjustments, the Tanzanian government has demonstrated a strong commitment, allocating TSh202 billion (approximately $9.7 billion USD) for the period between March and June 2025 to cushion current deficits. A substantial portion of this, TSh93.16 billion (around $4.5 billion USD), has already been channeled towards acquiring essential medications for HIV, tuberculosis, and malaria.

“This marks a significant step towards strengthening domestic investment in health product manufacturing,” Minister Mhagama affirmed, as reported by The Citizen.

Beyond the creation of new facilities, the government is also laser-focused on breathing new life into existing pharmaceutical infrastructure. A key component of this strategy involves a government-backed program, spearheaded by the Medical Stores Department (MSD), to revive the Tanzania Pharmaceutical Industries (TPI) factory located in the Arusha region. This factory, allocated TSh173.94 billion (approximately $8.4 billion USD), is earmarked to resume full-scale production of ARV drugs, along with medicines for malaria, tuberculosis, leprosy, HIV/Aids, hepatitis, and STIs.

The combined efforts of establishing new factories and revitalizing TPI are expected to dramatically improve the availability of vital medicines across Tanzania. By manufacturing drugs locally, the nation can ensure a more reliable supply chain, reduce costs associated with imports, and generate crucial employment opportunities within the burgeoning pharmaceutical manufacturing sector.

This initiative is a clear testament to Tanzania’s broader commitment to fortifying its healthcare system and fostering domestic industrial growth. As the global demand for medical products continues its upward trajectory, Tanzania’s proactive expansion of its pharmaceutical manufacturing capacity positions it as a key player in the region’s health sector.

The government’s commitment extends beyond drug production. An additional Sh309.51 billion (approximately $14.9 billion USD) has been allocated to enhance healthcare services across all public hospitals, with a particular emphasis on streamlining digital operations. Furthermore, TSh166.01 billion (around $7.9.

billion USD) has been set aside for combating communicable and non-communicable diseases, and TSh123.93 billion (approximately $5.9 billion USD) has been earmarked for advanced medical procedures, including liver transplants.

To ensure the delivery of quality healthcare, TSh80.38 billion (around $3.9 billion USD) will be utilized to recruit skilled healthcare workers nationwide, while another TSh76.57 billion (approximately $3.7 billion USD) is dedicated to combating maternal and infant mortality.

In a move towards comprehensive healthcare access, TSh9.80 billion (approximately $470.9 million USD) has been allocated for the implementation of the Universal Health Insurance Act, and TSh6.61 billion (around $317.7 million USD) will boost mental health and rehabilitation services. Even traditional medicine is seeing an investment, with TSh937.29 million (approximately $45 million USD) set aside to integrate it into 21 regional referral hospitals, up from the current 14.

Tanzania’s strategic investment in its pharmaceutical and healthcare sectors marks a pivotal moment, signaling a future where the nation is less reliant on external aid and more self-sufficient in meeting the health needs of its people.